Japanese Government Procurement
National University Corporation - Notice of Procurement (Goods & Services)Nivolumab (Genetical Recombination) 240mg 24mL/vial 1,395 cases,and 13 other contracts
This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.
| Publishing date | Jan 23, 2023 |
|---|---|
| Type of notice | Notice of Procurement (Goods & Services) |
| Procurement entity | National University Corporation - Ishikawa |
| Classification |
0004 Medical & Pharmaceutical Products |
| Summay of notice | ⑴ Official in charge of disbursement of the procuring entity : Takashi Wada, President, Kanazawa University ⑵ Classification of the products to be procured : 4 ⑶ Nature and quantity of the products to be purchased : A Nivolumab (Genetical Recombination) 240mg 24mL/vial 1,395 cases B Lenalidomide Hydrate 5mg 40 cap- sules/case 92 cases C Pembrolizumab (Genetical Recombination) 100mg 4mL/vial 2,025 cases D Pegfilgrastim (Genetical Recombination) 3.6mg 0.36mL/syringe 636 cases E Nusinersen Sodium 12mg 5mL/vial 5 cases F onasemnogene abeparvovec Per patient 1 case G tisagenlecleucel Per patient 3 cases H lisocabtagene maraleucel Per patient 8 cases I Atezolizumab (Genetical Recombination) 1,200mg 20mL/vial 570 cases J idecabtagene vicleucel Per patient 1 case K human (autologous) mesenchymal stem cells derived from bone marrow Once 1 case L Eculizumab (Genetical Recombination) 300mg 30mL/vial 186 cases M Ravulizumab (Genetical Recombination) 1,100mg 11mL/vial 50 cases N Ravulizumab (Genetical Recombination) 300mg 3mL/vial 141 cases ⑷ Delivery period : From 01 April, 2023 through 31 March, 2024 ⑸ Delivery place : Kanazawa University Hospital ⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article 30 and 31 of the Regulation concerning the Contract for Kanazawa University, B have the Grade A, Grade B, Grade C or Grade D qualification during fiscal 2023 in the Tokai・Hokuriku area in sales of product for participating in tenders by Single qualification for every ministry and agency, C prove to have obtained the first-class license for selling drugs in accordance with the Pharmaceutical and Medical Device Act, D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the Obligating Officer, E meet the qualification requirements which President, Kanazawa University may specify in accordance with Article 32 paragraph 3 of the Regulation, F not be currently under a suspension of business order as instructed by President, Kanazawa University. ⑺ Time limit of tender : 17 : 00 16 March, 2023 ⑻ Contact point for the notice : Yasuhiko Nakamura, Procurement management Section, Hospital Management Division, Hospital Department, Kanazawa University, 13-1 Takara-machi Kanazawa-shi 920-8641 Japan, TEL 076-265-2067 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents. |
